Rosiglitazone improves insulin sensitivity with increased serum leptin levels in patients with type 2 diabetes mellitus

Hae Jin Kim, Soo Kyung Kim, Wan Sub Shim, Jae Hyuk Lee, Kyu Yeon Hur, Eun Seok Kang, Chul Woo Ahn, Sung Kil Lim, Hyun Chul Lee, Bong Soo Cha

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Rosiglitazone (RSG) is known to be an agonist for the peroxisome proliferator-activated receptor-γ (PPARγ) and promotes differentiation of pre-adipocytes into adipocytes. Leptin is highly correlated with adiposity, while the activation of PPARγ is known to inhibit Lep gene expression and leptin release. This study was performed to evaluate the relationship between changes in circulating leptin levels, insulin sensitivity and regional adiposity after RSG treatment. Two hundred fifty-one type 2 diabetic patients (176 men and 75 women) who had been treated with sulfonylurea and/or metformin received 4 mg of RSG daily, in addition to the previous medications. Before and after RSG treatment (average duration 5.6 ± 0.9 months), indices of insulin resistance, metabolic parameters, and serum leptin and adiponectin levels were measured. Abdominal subcutaneous fat thickness (SFTmax) and visceral fat thickness were measured by sonography. After RSG treatment, HOMA-IR index decreased significantly (2.82 ± 1.94 vs. 2.01 ± 1.58), while BMI and SFTmax increased, and leptin (4.72 ± 3.77 vs. 5.69 ± 4.30 ng/ml) and adiponectin levels (7.54 ± 10.20 vs. 12.89 ± 10.13 μg/ml) increased. The increase in serum leptin correlated with an increase in SFTmax (r = 0.511, p < 0.001) and with a reduction in HOMA-IR (r = -0.368, p < 0.001). The correlation of Δleptin with ΔHOMA-IR and with ΔSFTmax was higher in females and among insulin-resistant subjects. In conclusion, RSG improves the insulin sensitivity with increased serum leptin levels in patients with type 2 diabetes mellitus, which is related to an increase in subcutaneous adiposity.

Original languageEnglish
Pages (from-to)42-49
Number of pages8
JournalDiabetes Research and Clinical Practice
Volume81
Issue number1
DOIs
Publication statusPublished - 2008 Jul 1

Fingerprint

rosiglitazone
Leptin
Type 2 Diabetes Mellitus
Insulin Resistance
Serum
Adiposity
Peroxisome Proliferator-Activated Receptors
Adiponectin
Adipocytes
Abdominal Subcutaneous Fat
Intra-Abdominal Fat
Metformin

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Kim, Hae Jin ; Kim, Soo Kyung ; Shim, Wan Sub ; Lee, Jae Hyuk ; Hur, Kyu Yeon ; Kang, Eun Seok ; Ahn, Chul Woo ; Lim, Sung Kil ; Lee, Hyun Chul ; Cha, Bong Soo. / Rosiglitazone improves insulin sensitivity with increased serum leptin levels in patients with type 2 diabetes mellitus. In: Diabetes Research and Clinical Practice. 2008 ; Vol. 81, No. 1. pp. 42-49.
@article{c51d0ebdebde43698ae358d97751d160,
title = "Rosiglitazone improves insulin sensitivity with increased serum leptin levels in patients with type 2 diabetes mellitus",
abstract = "Rosiglitazone (RSG) is known to be an agonist for the peroxisome proliferator-activated receptor-γ (PPARγ) and promotes differentiation of pre-adipocytes into adipocytes. Leptin is highly correlated with adiposity, while the activation of PPARγ is known to inhibit Lep gene expression and leptin release. This study was performed to evaluate the relationship between changes in circulating leptin levels, insulin sensitivity and regional adiposity after RSG treatment. Two hundred fifty-one type 2 diabetic patients (176 men and 75 women) who had been treated with sulfonylurea and/or metformin received 4 mg of RSG daily, in addition to the previous medications. Before and after RSG treatment (average duration 5.6 ± 0.9 months), indices of insulin resistance, metabolic parameters, and serum leptin and adiponectin levels were measured. Abdominal subcutaneous fat thickness (SFTmax) and visceral fat thickness were measured by sonography. After RSG treatment, HOMA-IR index decreased significantly (2.82 ± 1.94 vs. 2.01 ± 1.58), while BMI and SFTmax increased, and leptin (4.72 ± 3.77 vs. 5.69 ± 4.30 ng/ml) and adiponectin levels (7.54 ± 10.20 vs. 12.89 ± 10.13 μg/ml) increased. The increase in serum leptin correlated with an increase in SFTmax (r = 0.511, p < 0.001) and with a reduction in HOMA-IR (r = -0.368, p < 0.001). The correlation of Δleptin with ΔHOMA-IR and with ΔSFTmax was higher in females and among insulin-resistant subjects. In conclusion, RSG improves the insulin sensitivity with increased serum leptin levels in patients with type 2 diabetes mellitus, which is related to an increase in subcutaneous adiposity.",
author = "Kim, {Hae Jin} and Kim, {Soo Kyung} and Shim, {Wan Sub} and Lee, {Jae Hyuk} and Hur, {Kyu Yeon} and Kang, {Eun Seok} and Ahn, {Chul Woo} and Lim, {Sung Kil} and Lee, {Hyun Chul} and Cha, {Bong Soo}",
year = "2008",
month = "7",
day = "1",
doi = "10.1016/j.diabres.2008.02.001",
language = "English",
volume = "81",
pages = "42--49",
journal = "Diabetes Research and Clinical Practice",
issn = "0168-8227",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

Rosiglitazone improves insulin sensitivity with increased serum leptin levels in patients with type 2 diabetes mellitus. / Kim, Hae Jin; Kim, Soo Kyung; Shim, Wan Sub; Lee, Jae Hyuk; Hur, Kyu Yeon; Kang, Eun Seok; Ahn, Chul Woo; Lim, Sung Kil; Lee, Hyun Chul; Cha, Bong Soo.

In: Diabetes Research and Clinical Practice, Vol. 81, No. 1, 01.07.2008, p. 42-49.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Rosiglitazone improves insulin sensitivity with increased serum leptin levels in patients with type 2 diabetes mellitus

AU - Kim, Hae Jin

AU - Kim, Soo Kyung

AU - Shim, Wan Sub

AU - Lee, Jae Hyuk

AU - Hur, Kyu Yeon

AU - Kang, Eun Seok

AU - Ahn, Chul Woo

AU - Lim, Sung Kil

AU - Lee, Hyun Chul

AU - Cha, Bong Soo

PY - 2008/7/1

Y1 - 2008/7/1

N2 - Rosiglitazone (RSG) is known to be an agonist for the peroxisome proliferator-activated receptor-γ (PPARγ) and promotes differentiation of pre-adipocytes into adipocytes. Leptin is highly correlated with adiposity, while the activation of PPARγ is known to inhibit Lep gene expression and leptin release. This study was performed to evaluate the relationship between changes in circulating leptin levels, insulin sensitivity and regional adiposity after RSG treatment. Two hundred fifty-one type 2 diabetic patients (176 men and 75 women) who had been treated with sulfonylurea and/or metformin received 4 mg of RSG daily, in addition to the previous medications. Before and after RSG treatment (average duration 5.6 ± 0.9 months), indices of insulin resistance, metabolic parameters, and serum leptin and adiponectin levels were measured. Abdominal subcutaneous fat thickness (SFTmax) and visceral fat thickness were measured by sonography. After RSG treatment, HOMA-IR index decreased significantly (2.82 ± 1.94 vs. 2.01 ± 1.58), while BMI and SFTmax increased, and leptin (4.72 ± 3.77 vs. 5.69 ± 4.30 ng/ml) and adiponectin levels (7.54 ± 10.20 vs. 12.89 ± 10.13 μg/ml) increased. The increase in serum leptin correlated with an increase in SFTmax (r = 0.511, p < 0.001) and with a reduction in HOMA-IR (r = -0.368, p < 0.001). The correlation of Δleptin with ΔHOMA-IR and with ΔSFTmax was higher in females and among insulin-resistant subjects. In conclusion, RSG improves the insulin sensitivity with increased serum leptin levels in patients with type 2 diabetes mellitus, which is related to an increase in subcutaneous adiposity.

AB - Rosiglitazone (RSG) is known to be an agonist for the peroxisome proliferator-activated receptor-γ (PPARγ) and promotes differentiation of pre-adipocytes into adipocytes. Leptin is highly correlated with adiposity, while the activation of PPARγ is known to inhibit Lep gene expression and leptin release. This study was performed to evaluate the relationship between changes in circulating leptin levels, insulin sensitivity and regional adiposity after RSG treatment. Two hundred fifty-one type 2 diabetic patients (176 men and 75 women) who had been treated with sulfonylurea and/or metformin received 4 mg of RSG daily, in addition to the previous medications. Before and after RSG treatment (average duration 5.6 ± 0.9 months), indices of insulin resistance, metabolic parameters, and serum leptin and adiponectin levels were measured. Abdominal subcutaneous fat thickness (SFTmax) and visceral fat thickness were measured by sonography. After RSG treatment, HOMA-IR index decreased significantly (2.82 ± 1.94 vs. 2.01 ± 1.58), while BMI and SFTmax increased, and leptin (4.72 ± 3.77 vs. 5.69 ± 4.30 ng/ml) and adiponectin levels (7.54 ± 10.20 vs. 12.89 ± 10.13 μg/ml) increased. The increase in serum leptin correlated with an increase in SFTmax (r = 0.511, p < 0.001) and with a reduction in HOMA-IR (r = -0.368, p < 0.001). The correlation of Δleptin with ΔHOMA-IR and with ΔSFTmax was higher in females and among insulin-resistant subjects. In conclusion, RSG improves the insulin sensitivity with increased serum leptin levels in patients with type 2 diabetes mellitus, which is related to an increase in subcutaneous adiposity.

UR - http://www.scopus.com/inward/record.url?scp=44649123582&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44649123582&partnerID=8YFLogxK

U2 - 10.1016/j.diabres.2008.02.001

DO - 10.1016/j.diabres.2008.02.001

M3 - Article

C2 - 18394743

AN - SCOPUS:44649123582

VL - 81

SP - 42

EP - 49

JO - Diabetes Research and Clinical Practice

JF - Diabetes Research and Clinical Practice

SN - 0168-8227

IS - 1

ER -